%0 Journal Article
%A Vallejo-Vaz, Antonio J
%A Bray, Sarah
%A Villa, Guillermo
%A Brandts, Julia
%A Kiru, Gaia
%A Murphy, Jennifer
%A Banach, Maciej
%A De Servi, Stefano
%A Gaita, Dan
%A Gouni-Berthold, Ioanna
%A Kees Hovingh, G
%A Jozwiak, Jacek J
%A Jukema, J Wouter
%A Gabor Kiss, Robert
%A Kownator, Serge
%A Iversen, Helle K
%A Maher, Vincent
%A Masana, Luis
%A Parkhomenko, Alexander
%A Peeters, André
%A Clifford, Piers
%A Raslova, Katarina
%A Siostrzonek, Peter
%A Romeo, Stefano
%A Tousoulis, Dimitrios
%A Vlachopoulos, Charalambos
%A Vrablik, Michal
%A Catapano, Alberico L
%A Poulter, Neil R
%A Ray, Kausik K
%A DA VINCI Study Investigators
%T Implications of ACC/AHA Versus ESC/EAS LDL-C Recommendations for Residual Risk Reduction in ASCVD: A Simulation Study From DA VINCI.
%D 2022
%U http://hdl.handle.net/10668/20496
%X Low-density lipoprotein cholesterol (LDL-C) recommendations differ between the 2018 American College of Cardiology/American Heart Association (ACC/AHA) and 2019 European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) guidelines for patients with atherosclerotic cardiovascular disease (ASCVD) ( DA VINCI was a cross-sectional observational study of patients prescribed lipid-lowering therapy (LLT) across 18 European countries. Ten-year cardiovascular risk (CVR) was predicted among ASCVD patients receiving stabilized LLT. For patients with LDL-C ≥ 70 mg/dl, the absolute LDL-C reduction required to achieve an LDL-C of  Of the 2039 patients, 61% did not achieve LDL-C  In ASCVD patients, achieving ESC/EAS LDL-C goals could result in a 2% additional ARR over 10 years versus the ACC/AHA approach.
%K Atherosclerotic cardiovascular disease
%K Cardiovascular disease prevention
%K Cardiovascular risk
%K LDL-C
%K Lipid-lowering
%K Statins
%~